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Background: In the two-stage randomised trial design, a randomly sampled subset of study participants are permitted
to choose their own treatment, while the remaining participants are randomised to treatment in the usual way.
Appropriate analysis of the data from both arms of the study allows investigators to estimate the impact on study
outcomes of treatment preferences that patients may have, in addition to evaluating the usual direct effect of treatment.
In earlier work, we showed how to optimise this design by making a suitable choice of the proportion of participants
who should be assigned to the choice arm of the trial. However, we ignored the possibility of some participants being
indifferent to the treatments under study. In this paper, we extend our earlier work to consider the analysis of two-stage
randomised trials when some participants have no treatment preference, even if they are assigned to the choice arm
and allowed to choose.
Methods: We compare alternative characterisations of the response profiles of the indifferent or undecided participants,
and derive estimates of the treatment and preference effects on study outcomes. We also present corresponding test
statistics for these parameters. The methods are illustrated with data from a clinical trial contrasting medical and surgical
interventions.
Results: Expressions are obtained to estimate and test the impact of treatment choices on study outcomes, as well as
the impact of the actual treatment received. Contrasts are defined between patients with stated treatment preferences
and those with no preference. Alternative assumptions concerning the outcomes of undecided participants
are described, and an approach leading to unbiased estimation and testing is identified.
Conclusions: Use of the two-stage design can provide important insights into determinants of study outcomes that
are not identifiable with other designs. The design can remain attractive even in the presence of participants with no
stated treatment preference.
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Clinical trial outcomes may be affected by preferences
that trial participants might have between the treatments
under comparison. Preference effects can be substantial
[1], but they are unobservable in standard trial designs;
however, they are estimable in the two-stage randomised
trial, in addition to the usual treatment effect [2, 3].
Using this design, a randomly sampled subset of patients* Correspondence: walter@mcmaster.ca
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remainder randomised to treatment in the usual way.
Estimated preference effects often provide additional
insight into determinants of the study response, beyond
that of the treatment effect alone [1–4]. As we have
reviewed elsewhere [1], several preference-based designs
have been employed in biomedical research in recent
years [5–18].
We previously showed how to optimise the two-stage
design by controlling the proportion of patients who are
allocated to the choice arm (and hence can choose their
treatment) versus the random arm (where they arele is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
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example, involving the management of women with ab-
normal cervical screening results [4, 5], the investigators
compared a novel intervention with standard care, which
effectively defined a treatment preference for all partici-
pants. However, in other situations, some participants
may have no treatment preference, despite being informed
about the alternatives. For instance, in our further
example discussed later [6, 7], 69% of participants in the
choice arm had no preferred treatment.
In general, patients may be unable or unwilling to
choose a treatment because they want the doctor to
decide, or through anxiety or a lack of information or
decision-making confidence. Note specifically that “no
preference” is the observed preference value obtained
after due process of presenting treatment options to the
patient, but it is not “missing” data.
No previous paper has discussed how to deal with pa-
tients who are indifferent to treatment choice, i.e., who
are “undecided”, in more than passing fashion. Apart
from our own previous work [1], parameter estimation
in the two-stage design has not been described. The pos-
sibility of undecided patients was mentioned when the
design was originally proposed by Rucker [2], but only
concerning significance testing. Rucker assumed that
such participants either did not exist, or that preference
effects did not apply to them. We show here that these
approaches result in potentially biased parameter esti-
mates, but also that alternative (and testable) assumptions
are possible. We believe this issue is an important gap in
the existing literature, on a topic with considerable prac-
tical applicability.
Our previous work assumed that all patients had a
treatment preference, but we now extend our methods
to allow for undecided patients. We obtain estimates,
variances and test statistics for various preference ef-
fects, and estimate the usual treatment effect in this
design. We provide a general characterisation of theFig. 1 The two-stage randomised trial designundecided group, including alternative assumptions
about their response profile, and we determine if these
assumptions are empirically testable.
We illustrate the calculations using actual trial data,
discuss alternative ways that data from undecided partic-
ipants can be used, and compare our analysis to that of
the original trial investigators. In our Discussion, we
consider the appeal of the two-stage design when partic-
ipants with no treatment preference occur, including
their impact on study feasibility and efficiency.
Methods
In the two-stage randomised trial design, participants
are first randomly divided between the random and
choice arms (see Fig. 1). In the random arm, participants
are randomised to treatments A or B in the usual way.
In the choice arm, participants are allowed to choose
their treatment if they have a preference, while partici-
pants with no preference are randomised.
Following Rucker [2], we adopt the model:
Y ijk ¼ μþ τi þ νj þ πij þ εijk ð1Þ
where Yijk is the study outcome for participant k who
receives treatment i (i = 1 for treatment A, 2 for treat-
ment B) and who is in treatment preference group j
(j = 1 for participants preferring A, j = 2 for partici-
pants preferring B, and j = 3 for participants with no
preference). The parameters τ, ν, and π characterise
the treatment, selection and preferences effects, as
defined below; ε is a random error term, assumed in-
dependent of the other terms. As previously, we mod-
ify Rucker’s notation by replacing σ with ν, to avoid
confusion between preference effects and standard
deviations that are required later.
To eliminate parameter redundancies, we add four sets
of constraints:
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αν1 þ βν2 þ γν3 ¼ 0;
απi1 þ βπi2 þ γπi3 ¼ 0; f or i ¼ 1; 2
and
π1j þ π2j ¼ 0 f or j ¼ 1; 2; 3:
where α, β and γ are the expected proportions of par-
ticipants in the choice arm who choose treatment A,
treatment B, or make no choice, respectively.
Table 1 gives our notation. To simplify the expressions
and their interpretation for estimates and test statistics
to be derived later, we retain Y as the response variable
in the random arm, but use X for the response in partici-
pants with a treatment preference in the choice arm,
again following the original formulation [2]. We also
denote V as the outcome among undecided participants
in the choice arm. The total sample size is N, with m
and n participants being allocated to the choice and
random arms. For simplicity we assume equal treatment
group sizes in the random arm.
Ideally, we would like to observe μij as the mean
response for participants in preference group j who
receive treatment i, for every (i, j) combination, but only
four of the six possible subgroups are observable. We
can observe participants in the choice arm who have a
treatment preference, with expected outcomes μ11 and
μ22 for participants who prefer and receive treatments A
or B, respectively. Because undecided participants are
re-randomised, we can estimate μ13 and μ23 from the
choice arm. The remaining two subgroups, corresponding
to μ12 and μ21 , are unobservable, because all participants
in the choice arm with a treatment preference will receive
that treatment.
Among the m participants in the choice group, there
are m1 and m2 who choose treatments A and B, respect-
ively. Among the remaining participants with noTable 1 Observations and parameters by group and actual treatmen
Actual treatment Choice arm (Total sample size = m
Choose A Choose B








μ12 and μ21 are not observablepreference, we assume that m3/2 are randomised to each
of A and B. In the random arm, there is only one ob-
served group for each treatment, containing unknown
mixtures of treatment preferences. Here we observe
samples of size n1 and n2 under treatments A and B.
Because of the potential effects of treatment prefer-
ences, we take a general approach and allow for different
expected outcomes for the corresponding treatment
groups in the choice and random arms, and for indiffer-
ent participants to have different expected outcomes
from the other observable groups. We comment later on
the implications of alternative assumptions concerning
the responses in the indifferent participants.
We define the direct treatment effect by Δτ = τ1 − τ2,
or equivalently μ1 − μ2. One can estimate Δτ from the
random arm, through the sample estimate Y 1 – Y 2 of
μ1 – μ2. By virtue of the randomisation, this estimate will
be unbiased, because participant preferences will be bal-
anced in expectation. However, the estimate will be less
precise than in a parallel group trial of the same total
size.
We now consider the selection and preference effects.
Because there are three preference groups, there are two
possible contrasts for each effect.
Selection effect
The first selection effect is defined by Δν = ν1 – ν2, being
the expected difference in responses between partici-
pants who would choose treatment A versus treatment
B, if allowed to do so. Equivalently
Δν ¼ μ11 þ μ21ð Þ− μ12 þ μ22ð Þ½ =2; ð2Þ
which involves two unobservable means, μ12 and μ21.
The first stage randomisation implies equal expected
distributions of preferences in the choice and random
arms. Hence, the mean for the random arm under treat-
ment A is a weighted average of the means in the three
preference groups; thust for the 2-stage randomised design
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from which the unobservable μ12 can be expressed in
terms of observable quantities, as
μ12 ¼ μ1−αμ11−γμ13½ =β;
and similarly for μ21. From (1) we can show that νj = ½
[μ1j + μ2j] – μ, for j = 1, 2. By substituting for the two
























To estimate Δν, we may substitute into (3) the six ob-
servable sample means, and empirical estimates of the
preference proportions from the choice arm, α ¼ m1=m,




¼ z1−z2ð Þ−γ^ w1−w2ð Þ½ = 2α^β^m
h i
ð4Þ
where z1 ¼ m1 X 1−Y 1
 
, z2 ¼ m2 X 2−Y 2
 
, w1 ¼ m1
X 1−V 1
 
and w2 ¼ m2 X 1−V 2
 
. If there are no indiffer-
ent participants (γ = 0, and hence β = 1 – α), result (4)
simplifies to the same estimator as in our previous work
([3], Eq. 2).
Preference effect
The preference effect can be regarded as the interaction
between a participant’s preferred treatment and the
treatment actually received, or equivalently the difference
between the treatment effects (A - B) for participants who
would have chosen A or B. It can be defined as
Δπ ¼ π11−π12−π21 þ π22ð Þ=2
or in terms of the mean outcomes
Δπ ¼ μ11−μ21ð Þ− μ12−μ22ð Þ½ =2
This involves the unobservables μ12 and μ21, but if we
again invoke the equivalence of the preference distribu-






















which involves only estimable quantities. Similarly to the




¼ z1 þ z2ð Þ−γ^ w1 þ w2ð Þ½ =½2α^β^m ð5Þ
Again, this devolves to a simpler previous result when
there are no undecided participants ([3], Eq. 3).Second contrasts for selection and preference effects
For the selection effect, we can define a second contrast as:
Δν
0 ¼ ν3− ν1 þ ν22
which represents the difference in outcomes between
participants with no preference vs. those with a definite
treatment preference. This is orthogonal to Δν, and can
be expressed as
Δν
0 ¼ μ13 þ μ23ð Þ−
1
2
μ11 þ μ21 þ μ12 þ μ22ð Þ
 
=2




½α μ11−μ1ð Þ þ β μ22−μ2ð Þ−2αβ μ11 þ μ22−μ13−μ23ð Þ
−γ α μ11−μ13ð Þ þ β μ22−μ23ð Þf g
when expressed in terms of estimable quantities. By
again substituting empirical sample means and prefer-
ence proportions, we have an estimator
Δν
0∧ ¼ ½ z1 þ z2ð Þ− w1 þ w2ð Þ þ ðα^−β^Þ w1−w2ð Þ=½4α^β^m:
Similarly, a suitable second contrast for the preference
effect is
Δπ










which represents the difference in treatment effects (A
vs. B) between participants with no preference vs. those
with any definite preference. It is orthogonal to Δπ, and




½α μ1−μ11ð Þ−β μ2−μ22ð Þ
þ2αβ μ11−μ22−μ13 þ μ23ð Þ þ γfα μ11−μ13ð Þ
−β μ22−μ23ð Þg
with a corresponding estimator
Δπ
0∧ ¼ ½− z1−z2ð Þ þ w1−w2ð Þ−ðα^−β^Þ w1 þ w2ð Þ=½4α^β^m
Significance tests and confidence intervals for selection
and preference effects
To test the null hypothesis of no selection effect (H0:
Δν = 0), we can use the inner component of (4) as a test
statistic, i.e.,
T ¼ z1−z2ð Þ−γ^ w1−w2ð Þ ð6Þ
An approximately normal z-statistic is given by z ¼ T
=var Tð Þ, where






 þ 2γ α2σ213 þ β2σ223 
þγ 1−4γð Þ αe1−βe2ð Þ2 þ γ2 αe21 þ βe22
 
−2γ α 1−2αð Þd1e1 þ β 1−2βð Þd2e2 þ 2αβ d1e2−e1d2ð Þ½ g
ð7Þ
with d1 = μ11 − μ1, d2 = μ22 − μ2, e1 = μ11 − μ13, e2 = μ22
− μ23, θ =m/N (the proportion of participants assigned
to the choice arm), and where we have assumed for
simplicity n1 = n2 =N/2. An outline of this and later
derivations is given in the Additional file 1.
Because Δν
∧















where cov denotes a covariance. This leads to
varðΔνÞ ≈
∧







fα 1−2αð Þd1−β 1−2βð Þd2
−αβ 1−4αð Þe1− 1−4βð Þe2½ g= 2αβm½ 2
ð9Þ
We can use variance (9) to establish a confidence
interval for Δν.
Similar results emerge for the preference effect Δπ.
For testing the null hypothesis of no preference effect
(H0: Δπ = 0) we use
T ¼ z1 þ z2ð Þ−γ^ w1 þ w2ð Þ
with
var Tð Þ ¼ mfαd21 þ βd22− αd1 þ βd2ð Þ2
þ 1−γð Þ2 ασ211 þ βσ222





þ2γ α2σ213 þ β2σ223
 þ γ 1−4γð Þ αe1 þ βe2ð Þ2
þγ2 αe21 þ βe22
 
−2γ½α 1−2αð Þd1e1 þ β 1−2βð Þd2e2
−2αβ d1e2−e1d2ð Þg
ð10Þ
This leads to a sample variance of the preference effect
itself asvarðΔπÞ ≈
∧







fα 1−2αð Þd1−β 1−2βð Þd2
þαβ 1−4αð Þe1− 1−4βð Þe2½ g= 2αβm½ 2
ð11Þ
Similar derivations are possible for testing and estimat-
ing the second contrasts Δν′ and Δπ′; for brevity these
are not shown here, but some simplified results are
given below.
The results derived thus far are completely general in
allowing for different variances in the various study
subgroups, and for sample variation in the preference
distribution within the choice arm. Considerable simpli-
fication occurs if these conditions are relaxed. First, we
may assume that the outcome variance is constant.
Second, we may ignore sample variability in the prefer-
ence distribution in the choice arm. We refer to the vari-
ances as unconditional when sample variability in
preferences is taken into account (as in Eqs. 7, 8, 9, 10
and 11), and conditional when the preference distribu-
tion is taken as fixed.
Making both assumptions together, the variances of












as do the variances of the second estimated contrasts:
var Δν^′
  ¼ var Δπ^ ′  ¼ σ2
16α2β2γm
½γ 1−γð Þ α−βð Þ2
þ2 α2 2βþ γð Þ2 þ β2 2αþ γð Þ2
 





(detailed derivations not shown). As shown later in our
example, the unconditional and conditional variances
may be numerically very similar. Thus, in many practical
situations, it will be sufficient to use the simpler condi-
tional results (12) and (13).
Possible assumptions for responses in undecided
participants
In the original development of the two-stage design [2],
Rucker proposed that one should either assume that
there were no undecided participants (γ = 0), or that
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effects (μi3 = μi for i = 1, 2, respectively). Because the
{μi3} are estimable from undecided participants within
the choice arm, one can test the null hypotheses H0: μ13
= μ1 and H0: μ23 = μ2 by comparing the outcomes of the
undecideds to their similarly treated counterparts in the
random arm. When testing selection and preference ef-
fects, these assumptions are equivalent to assuming that
e1 = e2 = 0; however, these terms appear in expressions
such as (7) and (9, 10 and 11), implying that ignoring
them can bias the test statistics or confidence intervals
of these parameters.
An alternative approach is to assume that μii = μi3 for
i = 1, 2, or that the expected outcomes are the same in
participants with or without a preference, for each treat-
ment. This amounts to the so-called “exclusion restric-
tion” whereby the expected outcome is determined only
by the treatment actually received. Again these assump-
tions are testable in the two-stage design, using data
from the choice arm.
Another strategy would be to exclude undecided par-
ticipants from the analysis. This approach would make it
appear (incorrectly) that all participants in the random
arm have a preferred treatment.
One can show that expressions (4) and (5) give con-
sistent estimators of the selection and preference effects
even in the presence of indifferent participants. Con-
versely if either set of assumptions above is adopted, but
is actually false, biased estimation will occur. The bias
will be important unless the proportion of indifferent
participants is small.
Results
To illustrate these calculations, we will use data from a
trial to compare alternative interventions for heavy men-
strual bleeding [6, 7]. The treatment options were sur-
gery or medical management without surgery. Women
were randomised to a “conventional trial” subgroup
(random arm) or to a “patient preference” subgroup
(choice arm). In the choice arm, women were asked if
they had a preference for one of the treatments, and if
so, they could have it.Table 2 Summary of results from a two-stage randomised trial of m
Actual treatment Choice arm (Total sample size = m)
Chose medical Chose surgical
Medical Sample size 19
Mean 16.6
SD 8.7
Surgical Sample size 21
Mean 5.9
SD 7.2There were 227 women with outcome data available,
of whom 130 (57%) were assigned to the choice arm.
Within the choice arm, 19 elected to take medical treat-
ment, and 21 decided to have surgery. The remaining 90
women (69%) had no preference, and were randomised
(45 to each treatment). Thus while the rate of undecided
participants was high, the two treatments were selected
in somewhat similar numbers by women who were able
to make a choice.
Table 2 summarises one principal study outcome, ob-
served using a bleeding score (higher values represent
poorer outcomes). There were 5 women in the choice
arm and 41 in the random arm who refused to partici-
pate after entering the study. The disparity in these
numbers has the potential to create biased comparisons
among the women who did agree to participate, but un-
fortunately outcomes are unavailable for the refusers.
The lower refusal rate in the choice arm is in the
expected direction, because some participants will be
attracted by possibly being able to choose their own
treatment.
The investigators noted some baseline similarities be-
tween those choosing or being randomised to treatment,
and they therefore aggregated the results from the ran-
domised women in the random and choice arms, and
reported outcomes only according to the actual treat-
ment. In this paper we are able to use more detailed data
on preferences within the choice arm (kindly provided
by the investigators), allowing us to structure the results
in the format of our Tables 1 and 2.
The direct effect of treatment (estimated from the ran-
dom arm), was 12.10, with a standard error of 1.54 based
on a standard deviation pooled over all the data. The
95% confidence interval was (9.1, 15.1), indicating a sig-
nificant treatment effect in the direction of better out-
comes for women having surgery.
The estimated first selection effect contrast Δν^ was
3.03; using the unconditional approach and allowing for
different subgroup variances, with standard error 6.72.
Testing this effect gives T = 18.6 (SD = 40.8); z = 0.46 (p
= 0.65, 2-sided test). The conditional standard error of Δ
ν^ when the outcome variance was taken as constantedical vs. surgical treatment
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than its unconditional counterpart. For simplicity, condi-
tional standard errors were used in all further analyses.
The second selection contrast Δν^′ was 0.57, with con-
ditional standard error 3.62. While there is no strong
evidence of selection effects, the first contrast indicates
better outcomes for women who would select surgery
(treatment B) if allowed to do so, this being in addition
to the direct benefit of surgery.
The two estimated preference effects are Δπ^ = 0.93
and Δ bπ′ = − 0.49 (standard error = 6.64 for both). The
first contrast, being positive (although not significant),
indicates that the medical versus surgical effect is greater
for women who preferred medical treatment.
We can also empirically test the alternative assump-
tions for the outcomes among the undecideds. First,
using Rucker’s approach [2], we can compare the out-
comes for women on medical treatment, between the
undecided participants and those in the random arm:
this gives a mean difference of 18.40–17.20 = 1.20 (z
= 0.77, p = 0.44). Similar analysis of the corresponding
groups of women on surgery gives z = − 0.51 (p = 0.61).
Second, an assessment of the “exclusion restriction”
assumption leads to similar findings, with only small dif-
ferences in outcomes between women who chose their
treatment in the choice arm, or were assigned to it in the
random arm. Hence, in this example, there is no
compelling evidence of systematically different out-
comes for undecided women. However, we feel it is
still advantageous to allow for the existence of un-
decided participants, in order to avoid bias. As noted
earlier, we do not recommend simply ignoring the
data from undecided participants.Discussion
We have extended the methodology for two-stage
randomised trials to allow for participants who do not
have a preferred treatment. As noted earlier, the two-
stage design has been used in a variety of settings, and
in some cases the selection and preference effects have
been important, even when lacking a large treatment
effect. From the perspective of shared decision-making
concerning treatment options, it would be important to
know about these effects.
Investigators who consider adopting the two-stage trial
design would presumably hope that most participants
have a preferred treatment. For instance, trials using pa-
tient decision aids try to improve patient understanding
of the treatment options and reduce the number of
patients who are uncertain about their treatment, to help
them make an informed choice reflecting their own
values [19]. For patients who are unable or unwilling to
choose, the decision will likely revert to the clinicianproposing a treatment, and obtaining the tacit consent
of the patient.
Despite the complication of undecided participants,
the two-stage design remains attractive to people who
do have a preferred treatment, and it still provides
important information that is unobtainable from a con-
ventional design. Preference effects may enhance the
direct effect of treatment (as in our example), or act in
the opposite direction. One may also compare the
responses of decided vs. undecided individuals, as this
may also be predictive of better or worse outcomes;
these comparisons are accessible through our defined
second contrasts of the selection and preference effects.
Depending on the context, it seems better to allow study
participants the option of declaring no preference, rather
than pressuring them into a “forced” choice of treat-
ment; in this scenario, “no preference” is a valid observa-
tion, and not “missing”. However, the question of
undecided patients may not arise in some circumstances,
for instance where one treatment is usual care (e.g., [4, 5]).
We remarked earlier that it is inappropriate to simply
ignore undecided participants in the choice arm, because
of the potential for bias. Interestingly, in our example
study [6, 7], the investigators elected to include the un-
decided participants, but they aggregated them with simi-
larly treated participants in the random arm. Because all
patients in this analysis are randomised, the estimated
treatment effect is unbiased, but it lacks generalizability
because participants with a declared preference are
excluded.
Despite the advantages of the two-stage design, it must
be recognised that the existence of undecided or indif-
ferent patients may reduce its appeal. First, if a large
proportion of participants cannot decide on treatment,
estimating all the effects of interest (treatment, selection
and preference effects) becomes less precise. Second, the
presence of undecided participants leads to greater ana-
lytic complexity. Finally, the burden of explaining the
study to participants may become unattractive if rela-
tively few people will actually be able to make a treat-
ment choice. However, the investigators in our example
found that using this design “did not affect recruitment”
compared to conventional approaches [6, 7]. Neverthe-
less, it should be noted that despite this encouraging
finding, outcomes may still differ between participants
in the random arm and the subgroup who are rando-
mised within the choice arm.
In our example [6, 7], there was a high proportion of
undecided participants, with less than one third of the
patients in the choice arm declaring a preference. In this
study, the information sheet for women in the choice
arm contained only two additional sentences (“We do
realise that some women may have a preference for one
of the treatments. If you feel strongly that you want one
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to the information provided in the random arm. The
mention of “strong” preferences may have deterred some
women from choosing a treatment for which they had
only a weaker preference. Researchers carrying out pref-
erence trials should consider carefully the methods they
use to elicit preferences and their impact on the prefer-
ences that participants feel able to express.
Participants with no preference were also documented
in another two-stage design [9], a trial comparing medica-
tion and cognitive behavioural therapy for the treatment
of depression. Preferences were recorded on a 5-point
scale, with participants (19%) who chose the middle value
being defined as having “no clear treatment preference” or
“indecisive”. In other examples of the two-stage design
[8, 16–18, 20], no undecided participants were re-
ported, but it is unclear if such individuals were simply
ignored, or if initially undecided persons were somehow
persuaded to make a definitive choice before continu-
ing into the study.
Further work is required to extend our earlier results
[3] on optimising study efficiency while allowing for un-
decided participants. Optima here will depend on the
proportion of participants who can decide on a treat-
ment, as well as factors such as the preference rates for
the two treatments among the decided individuals. The
preference distribution will also affect the power to
detect selection and preference effects [21].
We limited our attention to trials with equal numbers
of participants being assigned to each treatment group
in the random arm. Another research topic of future
interest will therefore be to extend our methods to allow
for unequal treatment group sizes. Unequal assignments
might be desirable for ethical reasons, for instance if
there is a large majority preference for one treatment, or
if one treatment has a larger response variance. In such
cases, the investigators might wish to to improve study
efficiency, by striving for overall balance in the trial, for
example. We have discussed the ethics of unequal ran-
domisation in somewhat more detail elsewhere [1].
We adopted a model in which preferences were
assumed to have fixed effects. This was to conform to
Rucker’s original development, and indeed to our own
earlier work in this area, which we have extended here.
A further interesting extension would be to allow for
preferences (and, potentially, the treatment) to have ran-
dom effects. We note that all our estimates and tests are
based on large sample normal approximations, and fur-
ther work would be needed to consider small sample sit-
uations. One could, for instance, replace our z-statistics
with t-statistics. Our previous work on sample size and
power for the two-stage design [21] showed that particu-
larly small studies will be inadequate to reliably estimate
the parameters of interest. Rucker’s investigation ofempirical type I error rates showed excellent adherence
to nominal type I error rates with as few as 20 patients
in each of the random and choice arms [2]. These results
suggest that the large sample approximations described
here will be adequate for most practical problems.
A reviewer pointed out that participants in the ran-
dom arm may be randomised to a treatment that they
do not like, and this in turn may influence outcomes.
This is a valid point, but one that also affects a number
of other designs, including standard parallel group trials,
in exactly the same way. It has previously been noted
that parallel group trials involve arms that may not be
comparable after randomisation, because some patients
will be pleased to get their preferred treatment, while
others will be disappointed (this assuming that partici-
pants are not blinded) [22]. This phenomenon has been
termed “reluctant acquiescence” [23], and it may in turn
affect the estimated treatment effect. To the extent this
is a problem for the two-stage design, exactly the same
problem exists in parallel group designs, in terms of the
impact on the estimated treatment effect. However, note
that because the estimates of the selection and prefer-
ence effects in a two-stage design are based partly on
the data from the random arm, there may also be sub-
sidiary implications for those estimates as well.
There are related issues in a variety of other preference-
based designs, as we have reviewed elsewhere [1]. For
example, there are challenges in how to present informa-
tion about treatments and then eliciting preferences reli-
ably, and one must recognise that there are potential
differences between what are stated as the preferences for
treatment in a general sense, and actual treatments chosen
when participants are allowed to choose.
As we have reviewed elsewhere [1], randomised trial
designs can allow for patient preference effects in vari-
ous ways. There is also some literature on the impact of
clinician preferences for treatments, and the associated
“expertise bias” [24, 25]. The various designs that ac-
commodate patient or clinician preferences are differen-
tiated by whose preference is ascertained, how and when
they are measured, and if treatment assignments take
those preferences into account. Among these designs,
the two-stage approach is unique in being able to esti-
mate selection and preference effects in addition to the
direct treatment effects [26, 27]. It remains a candidate
design even when the complication of indifferent partici-
pants arises. The results in this paper have shown how
the information from such participants can be used in
the analysis for two-stage trials, to further elucidate the
impact of treatment preferences on study outcomes.
Conclusions
Treatment preferences among clinical trial participants
are potentially important determinants of study outcomes,
Walter et al. BMC Medical Research Methodology  (2017) 17:29 Page 9 of 10and we have demonstrated how data from two-stage ran-
domised trials can be analysed to estimate such effects.
We have extended our earlier work to now allow for the
possibility of participants who are indifferent or undecided
about a preferred treatment, and we discussed alternative
possible assumptions about their response patterns, com-
pared to participants with a declared treatment prefer-
ence. We also have shown how to obtain unbiased
estimates and tests of the preference effects in the trial as
a whole. Despite the presence of indifferent or undecided
participants, the two stage design is nevertheless an at-
tractive option for the examination of preference effects, a
feature which is not possible with conventional trial
designs.
Additional file
Additional file 1: The Appendix provides a more detailed outline of the
derivations of the test statistics and variances associated with estimates




We thank Dr KG Cooper for provision of data from his study, used in our
illustrative example.
Funding
This work was partially supported by funds from the Natural Sciences and
Engineering Research Council.
Availability of data and materials
All data generated or analysed during this study are included within this
published article. The study cited in references 6 and 7 provides the basis for
our illustrative example. Dr Kevin Cooper (Consultant Gynaecologist,
Aberdeen Royal Infirmary, Scotland) kindly provided additional details of the
study that were not shown in those references, and gave us permission to
use them in our published work. Specifically, these details were the provision
of summary statistics (sample sizes, means, and standard deviations) of the
study outcome variable, according to the randomly assigned arm of the
study, and according to the stated treatment preferences in the choice arm.
These summary statistics are shown within the current paper.
Authors’ contributions
All authors read and approved the final version of the manuscript. Their
specific contributions are as follows: SW: provided the overall leadership for
this work, and was primarily responsible for developing the analytic method
and for data analysis; wrote the initial and final drafts of the paper. RT:
contributed to the conception and design of the study, revised the
manuscript for important intellectual content, and agrees to be accountable
for all aspects of the work. PM: made substantial contributions to the
conception and design of the study, particularly interpretation and
derivation of equations; was involved in revising the manuscript for
important intellectual content, and takes public responsibility for the
content; agrees to be accountable for all aspects of the work in ensuring
that questions related to the accuracy or integrity of any part of the work
are appropriately investigated and resolved. KM: commented on multiple
drafts of the paper and made intellectual contribution to its content, and
agrees to be accountable for the work. LI: was involved in revising the
manuscript for important intellectual content; takes public responsibility for
the content; and agrees to be accountable for the work.
Authors’ information
None.Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
Not applicable.
Author details
1Department of Clinical Epidemiology and Biostatistics, McMaster University,
CRL 233, Hamilton, ON, CanadaL8N 3Z5. 2School of Public Health and
Community Medicine, University of New South Wales, Sydney, NSW 2052,
Australia. 3Screening and Test Evaluation Program, Sydney School of Public
Health, Sydney Medical School, University of Sydney, Sydney NSW 2006,
Australia.
Received: 16 August 2016 Accepted: 2 February 2017
References
1. Walter SD, Turner R, Macaskill P, McCaffery K, Irwig L. Beyond the treatment
effect: evaluating the effects of patient preferences in randomised trials. Stat
Methods Med Res. 2014. doi:10.1177/0962280214550516.
2. Rucker G. A two-stage trial design for testing treatment, self-selection and
treatment preference effects. Stat Med. 1989;8:477–85.
3. Walter SD, Turner RM, Macaskill P, McCaffery K, Irwig L. Optimal allocation of
participants for the estimation of selection, preference and treatment
effects in the two-stage randomised trial design. Stat Med. 2012;31:1307–22.
4. McCaffery KJ, Turner R, Macaskill P, Walter SD, Chan SF, Irwig L. Determining
the impact of informed choice: separating treatment effects from the
effects of choice and selection in randomised trials. Med Decis Making.
2011;31:229–36.
5. McCaffery KJ, Irwig L, Turner R, Chan SF, Macaskill P, Lewicka M, Clarke J,
Weisberg E, Barratt A. Psychosocial outcomes of three triage methods for
the management of borderline abnormal cervical smears: an open
randomised trial. BMJ. 2010;340:b4491.
6. Cooper KG, Grant AM, Garratt AM. The impact of using a partially
randomised patient preference design when evaluating alternative
managements for heavy menstrual bleeding. Br J Obstet Gynaecol. 1997;
104:1367–73.
7. Cooper KG, Parkin DE, Garratt AM, Grant AM. Two-year follow up of women
randomised to medical management or transcervical resection of the
endometrium for heavy menstrual loss: clinical and quality of life outcomes.
Br J Obstet Gynaecol. 1999;106:258–65.
8. Floyd AHL, Moyer A. Effects of participant preferences in unblinded
randomized controlled trials. J Empir Res Hum Res Ethics. 2010;8:81–93.
9. Mergl R, Henkel V, Allgaier AK, Kramer D, Hautzinger M, Kohnen R, Coyne J,
Hegerl U. Are treatment preferences relevant in response to serotonergic
antidepressants and cognitive-behavioural therapy in depressed primary
care patients? Results from a randomized controlled trial including a
patients’ choice arm. Psychother Psychosom. 2011;80:39–47.
10. Rokke PD, Tomhave JA, Jocic Z. The role of client choice and target
selection in self-management therapy for depression in older adults.
Psychol Aging. 1999;14:155–69.
11. Long Q, Little RJ, Lin X. Causal inference in hybrid intervention trials
involving treatment choice. J Am Stat Assoc. 2008;103:474–84.
12. Janevic MR, Janz NK, Dodge JA, Lin X, Pan W, Sinco BR, Clark NM. The role
of choice in health education intervention trials: a review and case study.
Soc Sci Med. 2003;56:1581–94.
13. Rose JP, Geers AL, Rasinski HM, Fowler SL. Choice and placebo expectation
effects in the context of pain analgesia. J Behav Med. 2012;35:462–70.
14. Kernahan C, Bettencourt BA. Motivated processing of black and white
targets: the situation of choice versus assignment. Basic Appl Soc Psych.
2002;24:125–44.
15. Noel PH, Larme AC, Meyer J, Marsh G, Correa A, Pugh JA. Patient choice in
diabetes education curriculum. Nutritional versus standard content for type
2 diabetes. Diabetes Care. 1998;21:896–901.
16. Burke LE, Styn MA, Steenkiste AR, Music E, Warziski M, Choo J. A
randomized clinical trial testing treatment preference and two dietary
Walter et al. BMC Medical Research Methodology  (2017) 17:29 Page 10 of 10options in behavioural weight management: preliminary results of the
impact of diet at 6 months - PREFER study. Obesity. 2006;14:2007–17.
17. Burke LE, Hudson AG, Warziski MT, Styn MA, Music E, Elci OU, Sereika SM.
Effects of a vegetarian diet and treatment preference on biochemical and
dietary variables in overweight and obese adults: a randomized clinical trial.
Am J Clin Nutr. 2007;86:588–96.
18. Burke LE, Warziski MT, Styn MA, Music E, Hudson AG, Sereika SM. A
randomized clinical trial of a standard versus vegetarian diet for weight loss:
the impact of treatment preference. Int J Obes (Lond). 2008;32:166–76.
19. Stacey D, Légaré F, Col NF, Bennett CL, Barry MJ, Col NF, et al. Decision aids
for people facing health treatment or screening decisions. Cochrane
Database Syst Rev. 2014. doi:10.1002/14651858.
20. Eisenberg DM, Post DE, Davis RB, Connelly MT, Legedza AT, Hrbek A, et al.
Addition of choice of complementary therapies to usual care for acute low
back pain - a randomized controlled trial. Spine. 2007;32:151–8.
21. Turner RM, Walter SD, Macaskill P, McCaffery KJ, Irwig L. Sample size and
power when designing a randomised trial for the estimation of treatment,
selection and preference effects. Med Decis Making. 2014;34:711–9.
22. McPherson K, Chalmers I. Incorporating patient preferences into clinical
trials. BMJ. 1998;317:78.
23. Tilbrook H. Patients’ preferences within randomised trials: systematic review
and patient-level meta-analysis. BMJ. 2008;337:a1864.
24. Devereaux PJ, Bhandari M, Clarke M, Montori VM, Cook DJ, Yusuf S, et al.
Need for expertise-based randomized controlled trials. BMJ. 2005;330:88–91.
25. Walter SD, Ismaila AS, Devereaux PJ. for the SPRINT study investigators
(2008). Statistical issues in the design and analysis of expertise-based
randomized clinical trials. Stat Med. 2008;27:6583–96.
26. Goodman LA. On the exact variance of products. JASA. 1960;55:708–13.
27. Johnson NL, Kotz S, Balakrishnan N. Discrete multivariate distributions. New
York: John Wiley & Sons; 1997.•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
